For research use only. Not for therapeutic Use.
Laquinimod (Cat No.:I002839) is a potent immunomodulator with therapeutic potential in autoimmune diseases. It acts by modulating the activity of immune cells, particularly T cells, and monocytes, leading to a rebalancing of the immune response. Laquinimod has shown efficacy in multiple sclerosis and other autoimmune conditions by reducing inflammation and promoting neuroprotection. It exerts its immunomodulatory effects through a variety of mechanisms, including the inhibition of pro-inflammatory cytokines and the induction of anti-inflammatory pathways.
| Catalog Number | I002839 |
| CAS Number | 248281-84-7 |
| Molecular Formula | C19H17ClN2O3 |
| Purity | ≥95% |
| Target | immunomodulator |
| Solubility | DMSO: ≥60 mg/mL |
| Storage | Room Temperature |
| IUPAC Name | 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide |
| InChI | InChI=1S/C19H17ClN2O3/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24/h4-11,23H,3H2,1-2H3 |
| InChIKey | GKWPCEFFIHSJOE-UHFFFAOYSA-N |
| SMILES | CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)O |
| Reference | </br>1:Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024. PMID: 28243182 Free PMC Article</br>2:Laquinimod enhances central nervous system barrier functions. Lühder F, Kebir H, Odoardi F, Litke T, Sonneck M, Alvarez JI, Winchenbach J, Eckert N, Hayardeny L, Sorani E, Lodygin D, Flügel A, Prat A.Neurobiol Dis. 2017 Jun;102:60-69. doi: 10.1016/j.nbd.2017.02.002. Epub 2017 Feb 22. PMID: 28235673 </br>3:Kynurenine system and multiple sclerosis, pathomechanism and drug targets with an emphasis on laquinimod. Majláth Z, Annus Á, Vécsei L.Curr Drug Targets. 2016 Dec 23. [Epub ahead of print] PMID: 28017129 </br>4:Targeting /bad/ B cells in multiple sclerosis: Could laquinimod be part of the armamentarium? Forsthuber TG, Stuve O.Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e283. eCollection 2016 Oct. No abstract available. PMID: 27704037 Free PMC Article</br>5:Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression. Varrin-Doyer M, Pekarek KL, Spencer CM, Bernard CC, Sobel RA, Cree BA, Schulze-Topphoff U, Zamvil SS.Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e272. eCollection 2016 Oct. PMID: 27704036 Free PMC Article</br>6:Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R.Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152. Epub 2016 Sep 26. PMID: 27671624 Free PMC Article</br>7:Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree. Cutter GR, Knappertz V, Sasson N, Ladkani D.BMC Neurol. 2016 Sep 17;16:176. doi: 10.1186/s12883-016-0702-4. PMID: 27639853 Free PMC Article</br>8:The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor. Berg J, Mahmoudjanlou Y, Duscha A, Massa MG, Thöne J, Esser C, Gold R, Haghikia A.J Neuroimmunol. 2016 Sep 15;298:9-15. doi: 10.1016/j.jneuroim.2016.06.003. Epub 2016 Jun 9. PMID: 27609269 </br>9:Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652. PMID: 27528441 Free PMC Article</br>10:Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR.Exp Neurol. 2016 Sep;283(Pt A):121-8. doi: 10.1016/j.expneurol.2016.06.008. Epub 2016 Jun 11. PMID: 27296315 |
